BV-CHP in Anaplastic Large Cell Lymphoma: Real-World Study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well BV-CHP works in real-world patients with a type of lymphoma called anaplastic large cell lymphoma (ALCL). It also collects leftover tissue samples to learn more about the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with anaplastic large cell lymphoma (ALCL) that started in your skin or lymph nodes.
- You received BV-CHP (a combination of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone) as your first treatment for this lymphoma.
- You have a tissue sample from the original diagnosis that is stored in a wax block (not a small needle biopsy).
- You agree to sign a consent form to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This study collects information and samples from people with large B-cell lymphoma who are either too frail for standard chemo, or whose disease has come back after one prior treatment. The goal is to better understand how to treat these situations.
This trial tests a chemotherapy combination called CAOP (four drugs given together) for patients 65 and older with a type of lymphoma called peripheral T-cell lymphoma who have never received cancer treatment before. The goal is to see if this combination works well and is safe for older adults.
This trial tests adding a BCL-2 inhibitor drug to a standard chemotherapy regimen (HyperCVAD) for people newly diagnosed with T-cell lymphoblastic lymphoma. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug called AZD3470, given alone or with other cancer treatments, for people with certain types of lymphoma (Hodgkin's lymphoma or T-cell lymphoma). It aims to see if the drug is safe and effective for patients who have already tried other treatments.
Hear when a new Anaplastic Large Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.